Research programme: PARP inhibitor - TESAROAlternative Names: MK-2512
Latest Information Update: 30 Jul 2012
At a glance
- Originator Merck & Co
- Developer TESARO
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 31 May 2012 Suspended for Cancer in USA (unspecified route)